… efficacy, our findings give support to current guidelines prioritizing nirmatrelvir/ritonavir use over molnupiravir … Amid a pandemic wave of the Omicron variant, real-worldeffectiveness of …
D Paraskevis, M Gkova, K Mellou, G Gerolymatos… - medRxiv, 2023 - medrxiv.org
… recipients had a reduced risk for death (HR:0.34) and hospitalization (HR: 0.76), with mortality risks to be consistently lower among elderly patients with early antiviral use [20]. In a study …
YR Jang, Y Oh, JY Kim - Journal of Korean Medical Science, 2024 - ncbi.nlm.nih.gov
… use showed substantial clinical benefit, including a lower risk of all-cause mortality, in-… should compare the effectiveness and safety of nirmatrelvir-ritonavir and molnupiravir. This …
I Karniadakis, N Mazonakis, C Tsioutis… - Infectious Disease …, 2023 - mdpi.com
… trials and real-world studies investigating the efficacy of these … and real-world studies have demonstrated the efficacy of … mortality, as demonstrated using clinical trials and real-world …
D Paraskevis, M Gkova, K Mellou… - The Journal of …, 2023 - academic.oup.com
… recipients exhibited a reduced risk of death (HR, 0.34) and hospitalization (HR, 0.76), with mortality risks that were consistently lower among elderly patients and in response to early …
EYF Wan, VKC Yan, AHY Mok, B Wang… - Annals of internal …, 2023 - acpjournals.org
… molnupiravir or nirmatrelvir–ritonavir, this study aimed to assess the effectiveness of both drugs in reducing mortality and … the real-worldeffectiveness of molnupiravir and nirmatrelvir–…
C Burdet, F Ader - The Lancet, 2022 - thelancet.com
… plusritonavir), whereas the effect on mortality was not … for molnupiravir, and not evaluable for nirmatrelvirplusritonavir … the efficacy of both antivirals in preventing all-cause mortality was …
WC Kwok, MF Tsoi, SHI Leung, CK Tsui, TCC Tam… - Viruses, 2023 - mdpi.com
… hospitalization and mortality by 89… Real-world studies have also suggested the benefits of MOV and NMV-r. Early initiation of oral antivirals was associated with reduced risks of mortality …
L Cegolon, R Pol, O Simonetti, F Larese Filon… - Pharmaceuticals, 2023 - mdpi.com
… This observational, controlled real-world study assessed the efficacy of three different treatment courses on three separate endpoints among 386 high-risk COVID-19 patients, adjusting …